AltruBio Inc. presented AbGn-107 Phase 1a chemo-refractory GI cancer results at ASCO-GI 2020

Share Article

AltruBio Inc. http://www.altrubio.com, a clinical stage biotech company, has announced the presentation of AbGn-107 at the 2020 ASCO GI Cancer Symposium in January 24, 2020. AbGn-107 is an antibody-drug conjugate (ADC) that selectively targets a glycoepitope expressed on various gastrointestinal tumors.

AltruBio Inc. http://www.altrubio.com, a clinical stage biotech company, has announced the presentation of AbGn-107 at the 2020 ASCO GI Cancer Symposium in January 24, 2020. AbGn-107 is an antibody-drug conjugate (ADC) that selectively targets a glycoepitope expressed on various gastrointestinal tumors. This dose-escalation Phase 1 study, led by renowned oncologist Dr. Andrew Ko of the University of California San Francisco, was conducted in patients with chemo-refractory locally advanced, recurrent, or metastatic gastric, pancreatic, colorectal or biliary cancer. AbGn-107 showed a well-tolerated safety profile and acceptable PK profile, as well as preliminary signs of efficacy including several patients with prolonged disease control. The ongoing cohort expansion phase was initiated focusing on enrollment of patients with high expression of this glycoepitope target to further evaluate the safety and efficacy of this ADC.

About AbGn-107.
AbGn-107, an antibody equipped with AltruBio's proprietary linker-payload, targets novel tumor-associated antigens on the surface of certain gastrointestinal (GI) cancers including stomach, biliary system, pancreas, colon and rectum. The targeting antibody is conjugated with a potent toxin through a cleavable linker which could only be cleaved inside the tumor cells. AbGn-107 demonstrated an excellent antitumor efficacy in at least six established xenograft tumor models and a favorable safe profile in NHP toxicity studies. AbGn-107 binds to approximately 40-50% of pancreatic, gastric and biliary cancers and 20-25% of colorectal cancers.

About GI cancers
Pancreatic cancer is the third-leading cause of death from cancer in the United States, with a 5-year survival rate of about 6%, the lowest rate among all cancer types. Gastric cancer is the sixth most common cancer in the world and the third leading cause of cancer death worldwide. Colorectal cancer is the third most common cancer in the world. While the death rate from colorectal cancer is declining, it still remains the second most common cause of cancer-related death in the world. These sobering statistics highlight the need for more effective therapies and strategies that can improve the survival and quality of life of patients diagnosed with each of these malignancies.

About AltruBio Inc. (http://www.altrubio.com)
AltruBio is a privately held biotechnology company headquartered in the San Francisco Bay Area that is focused on developing novel antibody therapeutics for the treatment of immunological diseases with high unmet medical needs. Based on unique insights into immune tolerance and epitope dominance sciences, AltruBio’ pipeline includes two clinical stage product candidates: (i) Neihulizumab (AbGn-168H) an immune checkpoint agonist antibody targeting PSGL-1/CD162 that depletes unwanted activated T cells with proof of mechanism in four autoimmune and inflammatory diseases, and (ii) AbGn-107, an antibody-drug conjugate (ADC) employing a unique enzyme cleavable hydrophilic self-immolative linker and targeting a gastrointestinal tumor antigen. AbGn-107 has demonstrated encouraging results in chemo-refractory gastric, pancreatic, colorectal and biliary cancers.

Note on Forward-Looking Statements
Statements made in this news release that are not historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as expects, believes, intends, and similar expressions are intended to identify forward-looking statements. Actual results may differ materially from those projected in any forward-looking statement. Specifically, there are a number of important factors that could cause actual results to differ materially from those anticipated, such as the Company's ability to raise additional capital, and risks related to the Company's ability to initiate, and enroll patients in, planned clinical trials. You should not place undue reliance on any forward-looking statements. The Company assumes no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by law.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Edwin Powers
Visit website

Media

AltruBio Inc